[1] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2010年版). 实用肝脏病杂志,2011,14(2):81-89. [2] 范建高. 中国非酒精性脂肪性肝病诊疗指南(2010年修订版). 中国医学前沿杂志(电子版),2012,21(7): 4-10. [3] Jin X,Chen YP,Yang YD,et al. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS One,2012,7(3):e34198. [4] Fan JG,Chitturi S. Hepatitis B and fatty liver:causal or coincidental. J Gastroenterol Hepatol,2008,23:679-681. [5] Taylor BC,Yuan JM,Shamliyan TA,et a1. Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics:A systematic review of vidence.Hepatology,2009,49(Suppl 5):S85-95. [6] Estakhri A,Sari AA,Nedjat SN,et al. The effect of NAFLD (non-alcoholic fatty liver disease) on long-term outcome of chronic hepatitis B in Iranian patients. Open J Gastroenterol, 2012,2(1):18-21. [7] 朱银芳,过小叶,徐淑凡,等. 阿德福韦酯治疗YMMD变异的乙型肝炎肝硬化患者2年疗效观察.实用肝脏病杂志,2011,14(5):368-369. [8] 张莎莎,吕文良,张旭,等. 中西医治疗慢性乙型病毒性肝炎研究进展. 吉林中医药,2011,31(1):89-91. [9] 邱源旺,黄利华,胡泰洪. 3种方案治疗代偿期肝硬化YMDD变异患者的成本-效果分析. 中国现代应用药学,2012,27(6):548-551. [10] Shi JP,Fan JG,Wu R,et a1. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol,2008,31:1419-1425. |